Point of Care Coagulation Testing Products Market Analysis

Point of Care Coagulation Testing Products Market Analysis

The POC coagulation testing products market by test type is categorized into prothrombin time testing products, activated clotting time (ACT/APTT) testing products, and others. The prothrombin time testing products segment garnered USD 1.2 billion revenue size in the year 2022. The widely recognized importance of prothrombin time testing in anticoagulant therapy monitoring, bleeding risk assessment, and blood disorder management elevates its role. Furthermore, technological advancements, such as improved sensors and connectivity, have bolstered its accuracy and efficiency. Seamless integration with electronic health records (EHRs) and mobile devices has further improved its accessibility. Moreover, the segment's versatility across healthcare settings, from hospitals to home care, strengthens its appeal.

Based on product type, the point of care coagulation testing products market is segmented into instruments and consumables. The instruments segment accounted for over 63% market share in the year 2022 attributed to its fundamental role in ensuring accurate testing, coupled with advanced technological features. These instruments streamline testing procedures through automation and integration with electronic health records, enhancing efficiency and informed decision-making.
 

Moreover, their adaptability across various healthcare settings underscores their versatility. For instance, Sysmex has launched the automated blood coagulation analyzers CN-6500/CN-3500 in Japan. These analyzers employ the chemiluminescence enzyme immunoassay (CLEIA) principle, developed with HISCL, enabling flexible measurements for thrombosis and hemostasis tests, including molecular markers.

U.S. point of care coagulation testing products market accounted for USD 788 million revenue size in 2022. U.S. leadership is rooted by its robust healthcare infrastructure that fosters the integration of advanced medical technologies. The U.S.'s focus on preventive healthcare aligns well with the capabilities of point of care coagulation testing products, facilitating timely monitoring and management of blood disorders. Substantial investments in research and development have fuelled ongoing innovation in testing technology, resulting in products with heightened accuracy and efficiency.
 

For instance, according to the Centers for Disease Control and Prevention (CDC), the prevalence of hemophilia in the U.S. is observed in approximately 1 out of every 5,617 live male births. Furthermore, within the U.S., the population comprises an estimated 30,000 to 33,000 males living with hemophilia. Additionally, statistics indicate that between 60,000 to 100,000 Americans lose their lives due to deep vein thrombosis complications.